SOPHiA GENETICS SA (SOPH)
| Market Cap | 332.39M +65.1% |
| Revenue (ttm) | 81.18M +20.9% |
| Net Income | -80.94M |
| EPS | -1.18 |
| Shares Out | 71.79M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 46,184 |
| Open | 4.640 |
| Previous Close | 4.740 |
| Day's Range | 4.550 - 4.758 |
| 52-Week Range | 2.590 - 5.700 |
| Beta | 1.01 |
| Analysts | Strong Buy |
| Price Target | 7.50 (+61.99%) |
| Earnings Date | May 5, 2026 |
About SOPH
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North Americ... [Read more]
Financial Performance
In 2025, SOPHiA GENETICS's revenue was $77.27 million, an increase of 18.56% compared to the previous year's $65.17 million. Losses were -$79.00 million, 26.4% more than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for SOPH stock is "Strong Buy." The 12-month stock price target is $7.5, which is an increase of 61.99% from the latest price.
News
Sophia Genetics, Synnovis team on liquid biopsy testing for UK cancer patients
Sophia Genetics (SOPH) announced a partnership with Synnovis, one of England’s pathology providers, to bring liquid biopsy testing to lung and breast cancer patients across the U.K. as part of…
Synnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K.
LONDON, May 13, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in Ai-driven precision medicine, today announced a partnership with Synnovis, one of England's leading pathology pr...
SOPHiA GENETICS Earnings Call Transcript: Q1 2026
Q1 2026 saw 22% revenue growth, record platform usage, and strong global expansion, with adjusted gross margin at 75.4% and net dollar retention up to 117%. Guidance for 2026 is reaffirmed, with growth expected to accelerate in the second half as new customers come online.
Sophia Genetics reports Q1 EPS (27c), consensus (24c)
Reports Q1 revenue $21.69M, consensus $20.4M. “We started 2026 strong, delivering 22% year-over-year revenue growth and a record 108,000 genomic analyses on SOPHiA DDMTM,” said Jurgi Camblong, Chief E...
Sophia Genetics backs FY26 revenue view $92M-$94M, consensus $93.25M
Backs FY26 adjusted EBITDA view $29M-$32M. Camblong added, “Looking ahead, new business momentum remains strong. Exciting new applications, continued U.S. expansion, and rising interest from BioPharma...
SOPHiA GENETICS Reports First Quarter 2026 Results
BOSTON and ROLLE, Switzerland, May 5, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, today reported financial results for the first quarter ended...
SOPHiA GENETICS to Announce Financial Results for First Quarter 2026 on May 5, 2026
BOSTON and ROLLE, Switzerland, April 21, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for...
Mount Sinai Health System and SOPHiA GENETICS Announce Collaboration to Advance Precision Cancer Care from AACR 2026
SAN DIEGO and NEW YORK, April 16, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, today announced that the Mount Sinai Health System, one of the l...
Sophia Genetics price target raised to $8 from $7 at BTIG
BTIG raised the firm’s price target on Sophia Genetics (SOPH) to $8 from $7 and keeps a Buy rating on the shares. After having recently hosted two days of investor…
Sophia Genetics management to meet with Craig-Hallum
Meeting to be held in Milwaukee and Chicago on April 9 hosted by Craig-Hallum.
Sophia Genetics management to meet with BTIG
Meeting to be held in Boston on April 13 hosted by BTIG.
Sophia Genetics management to meet with Piper Sandler
Meeting to be held on April 2 hosted by Piper Sandler.
Sophia Genetics management to meet with Piper Sandler
Meeting to be held on April 2 hosted by Piper Sandler.
SOPHiA GENETICS Transcript: TD Cowen 46th Annual Health Care Conference
Leadership transition will bring a new CEO focused on commercial growth, with the founder moving to executive chairman. The company targets accelerated revenue growth through 2026, driven by U.S. market momentum, AI-powered platform differentiation, and expanding partnerships with leading academic centers.
Sophia Genetics files to sell 75,000 ordinary shares for holders
16:19 EST Sophia Genetics (SOPH) files to sell 75,000 ordinary shares for holders
Sophia Genetics reports Q4 EPS (28c) vs. (23c) last year
Reports Q4 revenue $21.7M vs. $17.7M last year. Performance in the quarter was driven by 45% year-over-year analysis growth in North America and 32% in Asia Pacific. “We finished 2025…
Sophia Genetics sees FY26 revenue $92M-$94M, consensus $76.47M
Sees FY26 revenue to represent approximately 20%-22% vs. last year. Sees FY26 adjusted EBITDA between ($29M)-($32M).
SOPHiA GENETICS Earnings Call Transcript: Q4 2025
Revenue grew 19% in 2025 to $77.3M, with strong Q4 and record customer signings. 2026 guidance targets 20–22% growth, improved margins, and adjusted EBITDA breakeven by year-end. Major U.S. health system wins and pharma partnerships drive future expansion.
SOPHiA GENETICS Reports Fourth Quarter and Full Year 2025 Results
BOSTON and ROLLE, Switzerland, March 3, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the fourth quarter an...
SOPHiA GENETICS to Present at the 46th Annual TD Cowen Health Care Conference
BOSTON and ROLLE, Switzerland, Feb. 25, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced that leadership will present at TD Cowen's...
SOPHiA GENETICS to Announce Financial Results for Fourth Quarter and Full Year 2025 on March 3, 2026
BOSTON and ROLLE, Switzerland, Feb. 17, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for ...
Sophia Genetics signs two major U.S. healthcare systems
Sophia Genetics (SOPH) added two of the largest U.S. healthcare systems to its network. The two new institutions, which collectively analyze millions of genetic samples annually, include one of the…
SOPHiA GENETICS Announces Major Expansion in the United States with the Signing of Two Major Integrated Health Systems
BOSTON and ROLLE, Switzerland, Feb. 10, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, today announced the addition of two of the largest U.S. he...
Sophia Genetics price target raised to $7 from $6 at Guggenheim
Guggenheim raised the firm’s price target on Sophia Genetics (SOPH) to $7 from $6 and keeps a Buy rating on the shares. The firm adjusted models, forecasts and targets for…
Sophia Genetics sees Q4 revenue ‘at least’ $21M, consensus $20.5M
“2025 was a tremendous year for SOPHiA GENETICS (SOPH) as we reaccelerated revenue growth and materially exceeded our new business bookings target, setting the stage for robust future growth,” said…